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Summary 
There is a strong association between Guillain-Barr~  syndrome (GBS) and Penner's serotype 19 
(PEN  19) of CamFflobacterjejuni.  Sera from patients with GBS after  C. jejuni infection have 
autoantibodies to GM1 ganglioside in the acute phase of the illness. Our previous work has 
suggested  that  GBS  results  from  an  immune response  to  cross-reactive  antigen  between 
lipopolysaccharide (LPS) of the Gram-negative bacterium and membrane components of peripheral 
nerves. To clarify the pathogenesis of GBS, we have investigated whether GMl-oligosaccharide 
structure is present in the LPS of C. jejuni (PEN 19) that was isolated from a GBS patient. After 
extraction of the LPS, the LPS showing the binding activity of cholera toxin, that specifically 
recognizes the GMl-oligosaccharide was purified by a silica bead column chromatography. Gas- 
liquid chromatography-mass spectrometric analysis has shown that the purified LPS contained 
Gal, GalNAc, and NeuAc, which are sugar components of GM1 ganglioside.  1H NMR methods 
[Carr-Purcell-Meiboom-Gill (CPMG),  total correlation spectroscopy (TOCSY),  and nuclear 
Overhauser effect spectroscopy (NOESY)] have revealed that the oligosaccharide structure [GalB1- 
3GalNAcB1-4(NenAcot2-3)GalB]  protrude from the LPS core. This terminal structure [GalB1- 
3GalNAcB1-4(NeuAcot2-3)GalB] is identical to the terminal tetrasaccharide of the GM1 ganglioside. 
This is the first study to demonstrate the existence of molecular mimicry between nerve tissue 
and the infectious agent that elicits GBS. 
G 
uillain-Barr6 syndrome (GBS) is the most common cause 
of acute neuromuscular paralysis in developed countries 
and it affects 1-2/100,000 people annually (1). Anti-neural 
antibodies may function in the development of GBS because 
plasma exchange elicits a beneficial response (1). Gangliosides, 
cell surface components of nerve tissue,  are considered the 
target antigens of anti-neural antibodies because  some pa- 
tients develop GBS after being administered them (2-6). The 
dependence of GBS on "molecular mimicry" between infec- 
tious agents and surface components of  peripheral nerves has 
been postulated (1). 15-40% of the GBS patients develop the 
syndrome after being infected by the Gram-negative bacte- 
A preliminary  report of this study  appeared  in Bioraed.  Res. 1992. 13:451. 
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rium Camt,ylobacterjejuni, a leading cause of acute gastroente- 
ritis in humans (7, 8). Sera from GBS patients who have had 
C. jejuni enteritis contain autoantibodies to GM1 ganglio- 
side (5, 6, 9-11). The bacterium can be serotyped on the differ- 
ence in the carbohydrate structure in the lipopolysaccharides 
(LPS) which are major constituents of the outer membrane 
of Gram-negative bacteria (12, 13, 14, 15). The specific sero- 
type of Penner's 19 (PEN 19) of C. jejuni is very frequently 
isolated from GBS patients (8, 16); whereas, it is rarely iso- 
lated in the case of C.jejuni enteritis.  We recently found anti- 
genic similarity between the GM1 ganglioside and the LPS 
of C. jejuni (PEN 19) (17). Present study of immunochem- 
ical and NMR  analyses on the LPS of C. jejuni has now 
confirmed molecular mimicry between the carbohydrate struc- 
ture of this LPS and that of GM1 ganglioside. 
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Case Report.  A 24-yr-old man developed watery diarrhea with 
fever, which improved over 4 d. 6 d after the resolution of this 
illness, he developed distal muscle weakness, and on day 4, prox- 
imal muscle weakness. He was admitted to the hospital 7 d after 
the onset of neurologic symptoms. Neurologic examination was 
significant  for  areflexia and  distal-dominant  muscle  weakness 
without superficial  or deep sensory disturbances. Muscles of respi- 
ration and cranial nerves were unaffected. The cerebrospinal fluid 
protein  level was increased with normal  cellularity. Serial dec- 
trophysiological  studies indicated that the predominant mechanism 
was axonal degeneration of the motor nerve. C.jejuni was isolated 
from his stool. The agent of antecedent infection was serologically 
determined using a complement fixation test; a high serum anti- 
body titer against C. jejuni and a more than fourfold change in 
titer indicated a preceding C. jejuni infection. In the acute phase 
of this neurologic disease, the patient's  serum antibody reacted 
strongly with GM1, and very faintly with GDlb as previously 
reported (17), but did not react with GDla, GTlb, GM2, and GQlb. 
Bacterium.  The bacterium used in this study was C. jejuni (CF 
90-26) from this GBS patient. Serotyping of C.jejuni was performed 
by the method of  Penner and Hennessy (12) and the strain belonged 
to PEN 19. Stock culture was maintained at  -80~  in glycerol 
and brain heart infusion broth (15:85, by volume, Difco Laborato- 
ries Inc., Detroit, MI). Culture was grown on Mueller-Hinton agar 
(Oxoid Ltd., Basingstoke, UK) at 37~  for 48 h in an atmosphere 
of 5% 02, 10% CO2, and 85% N2. The bacterium was harvested 
in physiological saline, centrifuged at 10,000 g (4~  30 min), and 
washed three times with physiological saline. 
Extraction of Crude LPS.  LPS was extracted from 20 g (wet 
weight) of C. jejuni (PEN 19) by the hot phenol-water technique 
(18). After keeping the fraction at 4~  overnight, the aqueous layer 
was dialyzed against distilled water. 2 vol of methanol and 1 vol 
of chloroform were added to the aqueous phase, after which I vol 
of chloroform, followed by I vol of water was added. The chloro- 
form layer was evaporated, and the dry residue was dissolved in 
25% NH4OH, and then incubated at 56~  for 48 h. After dial- 
ysis against distilled water, the crude LPS was lyophilized. 
Purification of LPS with GM1-oligosaccharide Structure.  100 mg 
crude LPS was dissolved in a solvent mixture of n-propanol-water- 
25%  NH4OH  (75:15:10, by volume).  This  LPS solution  was 
applied to a column (2  x  100 cm) packed with Iatrobeads (6RS- 
8060; Iatron,  Co., Tokyo, Japan) and duted with a gradient of 
n-propanol-water-25% NH4OH [75:15:10 (900 ml) to 6:4:1 (900 
ml), by volume]. Each fraction duted from the column was sub- 
jected to thin-layer chromatography  (TLC) and made visible by 
spraying precoated Silica  Gel 60 plates (E. Merck, Darmstadt, Ger- 
many) with ninhydrin, orcinol, resorcinol, and Dittmer reagents, 
and by binding of the peroxidase-conjugated cholera toxin subunit 
B (Vector  Laboratories, Burlingame, CA) which specifically  recog- 
nizes the GMl-oligosaccharide. A solvent system of n-propanol- 
water-25%  NH4OH (6:3:1, by volume) was the developer used. 
Fractions that showed homogeneous bands with the binding ac- 
tivity of the cholera toxin were pooled, evaporated, and the dry 
residue dissolved  in 20 ml of physiological  saline. The solution con- 
taining the LPS was applied to a Cls Sep-Pak cartridge (Millipore 
Corp., Bedford, MA), which was washed with 20 ml of water, 
and the pure LPS fraction was eluted with 20 ml methanol 
Gas-Liquid Chromatography--Mass Spectrometry (GC/MS).  50/xg 
purified LPS was subjected to methanolysis with 200 ILl 5% metha- 
nolic HC1 and 50/xl methylacetate at 700C for 16 h. Fatty acid 
methylesters were extracted with n-hexane, and the aqueous layer 
was used for sugar analysis. Fatty acid methylesters were analyzed 
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by GC/MS using a Varian 3400 gas chromatograph  (Varian As- 
sociates, Inc., Palo Alto, CA) interfaced to a TSQ 70 triple-stage 
quadrupole mass spectrometer (Finnegan MAT, San Jose, CA). The 
GC column was a DB-5 (0.25 mm i.d.  x  30 m; J&W Scientific 
Folsom, CA) chemically  bonded, fused silica, capillary  column. The 
temperature was programmed from 180 to 270~  at the rate of 
4~  Electron impact mass spectra were acquired from m/z 
40-650 at I s/scan. Electron energy was 70 eV. Ionization current 
was 200 #A. Ion source temperature was maintained at 150~ 
The aqueous layer-removed fatty acid methylesters was evapo- 
rated to dryness by the addition of 50/~1 of ten-butanol. Acetyla- 
tion was carried out for 20 rain by the addition of 100/~1 of meth- 
anol,  10/~1 of pyridine, and 10/tl of acetic anhydride at room 
temperature, and then the solvent was evaporated under nitrogen 
stream (19). 50/~1 of TMS reagent (consisting of 100/~1 of pyri- 
dine, 20 #1 of hexamethyldisilazane,  and 20/~1 of trimethylchlorosi- 
lane) was added, and the mixture was left for 20 min at room tem- 
perature. TMS sugars were analyzed  by GC/MS. GC/MS conditions 
were similar to analysis of fatty acid methylesters. 
Proton NMR Spectroscopy.  NMR experiments were performed 
on a JEOL JNM c~600 600 MHz 1H NMR spectrometer (Jeol 
Ltd., Tokyo,  Japan). A 1,5-mg sample of the purified LPS was dis- 
solved in 500 #1 of 2H20 and incubated at 60~  for 10 min to 
replace exchangeable protons with deuterons.  Then, the sample 
solution was lyophilized. The resulting residue was dissolved in 
500 #1 of ~H20, and the pH was "~7. All the measurements were 
made using 5-mm diameter sample tubes. 2,2-Dimethyl 2-silapen- 
tane-5-sulfonate was used as the internal standard of  chemical shift. 
Delays alternating with nutation for tailored excitation (DANTE) 
decoupling was performed to suppress residual HDO resonance. 
One-dimensional  NMK experiments  were performed  at 60~  Carr- 
PurceU-Meiboom-GiU  (CPMG) spectrum (20) was measured with 
a 100-ms delay time. 
Two-dimensional NMK spectra were recorded in the phase sen- 
sitive mode with 512(h)  x  1024(t2) data points (21, 22). Total 
correlation spectroscopy (TOCSY) spectrum was measured with 
a mixing time of 120 ms at 60~  Nuclear Overhauser effect spec- 
troscopy (NOESY) spectrum was measured with a mixing time 
of 200 ms at 40~  In total, 64 scans were made for each tl with 
a spectral width of 6,000 Hz. The digital resolution was 5.9 Hz 
in both dimensions with zero-filling in the tl dimension. The sine 
bell function  was applied to both the tl and t2 dimensions. 
Results and Discussion 
Fig.  1 shows chromatographic elution profile of the LPS 
from the Iatrobeads column. Fractions from 94 to 104 showed 
homogeneous bands when they were stained by the binding 
activity of cholera toxin and by ninhydrin reagents for amino 
groups, orcinol reagents for hexose, and resorcinol reagents 
for deoxy-keto sugar (Fig.  1), as well as Dittmer reagents 
for phosphorous groups (data not shown). GC/MS analysis 
showed that the purified LPS from C. jejuni (PEN 19) con- 
tained the following sugar components galactose (Gal), glu- 
cose, N-acetylgalactosamine (GalNAc), N-acetylneuraminic 
acid  (NeuAc),  and  heptose (Hep),  as  well  as  3-deoxy-2- 
octulosonic acid and the fatty acid components, 3-hydroxy- 
myristic acid and palmitic acid. These fatty acids are known 
to be the components of the lipid A  from C. jejuni  (23). 
Bacterium That Elicits Guillain-Barr~ Syndrome  Has GMl-like Structure a 
-~8  ....  5  ....  U A 
Figure  1.  Chromatographic profile of the LPS. Fractions eluted from 
the Iatrobeads column were subjected to TIC and made visible by spraying 
the plate with (a) ninhydrin,  (b) orcinol,  and (c) resorcinol reagents, and 
by the binding of (d) cholera toxin. 
Ethanolamine also was detected by the amino acid analysis 
(data not shown). 
Fig. 2 a shows the normal NMR spectrum of the purified 
LPS. The 3e and 3a proton resonances of NeuAc are present. 
Anomeric proton resonances a, b, c, and d suggests the pres- 
ence of sugars GalB,  Gal~/, GalNAc~, and Hepc~, respec- 
tively. The spectrum in Fig. 2 a has resonances with narrow 
and broad line widths, indicative of two components with 
different mobilities. This is supported by measurement of  the 
CPMG spectrum (Fig. 2 b), in which resonances with broad 
line widths were suppressed due to fast spin-spin relaxation 
times, whereas those with sharp line widths were enhanced. 
The resonances in Fig. 2 b correspond to protons located in 
the mobile region of the LPS. From the intensity of the ano- 
meric protons in the CPMG spectrum, the mobility of the 
sugar residues was estimated to the GalB(a)>GalNAc~(c)> 
Gal~(b)-Hepc~ (d), which supports the contention that these 
oligosaccharides extend from the LPS core. Fig. 3 a shows 
TOCSY spectrum of the LPS sample. Cross peaks produced 
by magnetization transfer  from the anomeric protons are 
present.  On the basis of these cross peak patterns,  the ano- 
meric protons a, b, c, and d were assigned to the sugar types 
Gal~, Gal~, GalNAc~, and Hepot shown in Fig. 3 a, respec- 
tively (21, 22). It should be noted that the H3 of Gal~(b) 
shifted as much as 0.5 ppm to the lower field, which is char- 
acteristic of the chemical shift change caused by the linkage 
formation of NemA_ccc2-3Gal. We therefore concluded that 
the LPS sample had the NeuAc~2-3Gal~(b) moiety. The other 
sugar linkages then were studied by NOESY. The cross peaks 
b 
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Figure  2.  One-dimensional  1H NMR. spectra of the LPS sample. (a) 
normal  spectrum,  (b) CPMG spectrum. 
developed  from the anomeric protons are connected by dotted 
lines in Fig. 3.  Taking into account  the chemical shifts of 
the individual sugar proton resonances  obtained in the TOCSY 
experiment, we identified the interresidual (boxed with solid 
lines) as well as the intraresidual NOESY cross peaks. Gal~(b) 
linked to the 2-position of the manno-type sugar. No man- 
nose was detected by GC/MS, Hep being the only sugar with 
the manno-confignration in  this  sample. The  linkage  of 
Gal3(a)l-3GalNAc~t(c)l-4(NeuAccl2-3)Gal/7(b)l-2Hepa(d) 
was confirmed from the interresidual cross peaks. On the basis 
of the mobility of the sugar residues (shown in Figs. 2 and 
3), this oligosaccharide chain must protrude from the LPS 
core,  because of which  the GMl-oligosaccharide  moiety 
[GalB(a)l-3GalNAc~(c)l-4(NeuAcc~2-3)Gal~(b)] may be ex- 
posed (Fig. 4). This terminal structure [GaI~I-3GalNAcB1-4 
(NeuAcc~2-3)GalB] is identical to the terminal tetrasaccha- 
ride of GM1 ganglioside (Fig. 4), thereby enabling this LPS 
to interact  with the cholera toxin. 
GM1 is enriched in the membrane of the motor nerve ter- 
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Figure  3.  Two-dimensional IH NMR spectra of the LPS sample. (a) 
TOCSY  spectrum.  TOCSY  cross peaks developed from the anomeric 
protons are connected by dotted lines. The assignments of the cross peaks 
also are shown. (b) NOESY spectrum. Interresidual NOESY cross peaks 
are boxed with solid lines. The sugar linkages are identified as Gal~(a)l- 
3GalNAc~(c)l-4(NeuAc~2-3)Gal~(b)l-2Hepc~(d) from the interresidual 
nuclear Overhauset effects. 
minal which lacks the blood-nerve barrier, and to which anti- 
neutral antibodies easily gain access (24). In a coculture system 
of rat motoneurons and human muscle cells in monolayer 
(25), monodonal anti-GM1 antibodies and serum anti-GMI 
antibodies from GBS patients, who previously had been in- 
oMI g.g,o.~d.  GalOl.3GalNAc~l:4Gal~l-4GIc[31-1'Cer 
NeuAcc~2 
LPS (PEN  19)  GaI01-3GalNAcOI-4GaI~I-2Hep~-LPS  core 
J 
NeuAc~2 
Figure  4.  Molecular mimicry between GM1 ganglioside and the LPS 
of C. jejuni (PEN 19). The same terminal tetrasaccharide (underline)  oc- 
cupies the nonreducing end of GM1 ganglioside and the LPS (PEN 19). 
fected by C. jejuni,  suppressed spontaneous firing and end- 
plate potentials; whereas, monodonal anti-GDla, anti-GDlb, 
anti-GTlb, and anti-GQlb antibodies did not (Kobayashi et 
al., unpublished data).  This finding indicates that the anti- 
GM1  antibody inhibits motoneuron excitability. 
Administration of GM1 ganglioside sometimes causes the 
development of GBS associated with anti-GM1 antibody (2, 
5, 6). Inoculation of rabbits with GMI and certain adjuvants 
can cause peripheral neuropathy (26, 27). LPS is a potent poly- 
donal adjuvant of immune responses, its lipid A moiety being 
a known B cell mitogen (28).  The LPS of C. jejuni (PEN 
19), which bears the GMl-oligosaccharide structure, appears 
to have high immunogenic  activity to produce anti-GM1 an- 
tibody. Sera from the GBS patient from whom C.jejuni (PEN 
19) was isolated had antibodies to GM1, but did not have 
antibodies to GDla, GTlb, GM2, or GQlb. In contrast, rabbit 
anti-GM1 antibody did not react with LPSs from other sero- 
types of C.jejuni, PEN 3, 5, or 11 (Yuki et al., unpublished 
data). Very recently, Aspinall et al. determined chemical struc- 
tures of side chains of LPSs from C. jejuni PEN 1, 2, 4, 23, 
and 36. The side chains described by them have terminal sugar 
structures of GM2, GM3, GDla, or GMlb; they do not have 
that of GM1.  Therefore, we speculate that infection by C. 
jejuni (PEN 19) induces high production of anti-GM1 anti- 
body in patients with an immunogenetic  background, thereby 
leading to the abolishment of tolerance,  and that the anti- 
GM1  antibody  binds  to  motor  nerve  terminals  causing 
motoneuron inexcitability and the eventual development of 
muscular weakness.  Ours is the first study to demonstrate 
the existence of molecular mimicry between nerve tissue and 
the infectious agent that elicits GBS (Fig.  4).  The results 
reported here should be of use in establishing the mechanism 
of the pathogenesis of GBS after infection as well as the mech- 
anisms of other autoimmune diseases. 
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